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 3 
INTRODUCTION  
 
Hepatocellular carcinoma (HCC) is the sixth commonest 
cancer worldwide with the fastest rising cause of cancer-
related deaths and a sharp increase in incidence over the past 
three decades [1].    
The mortality rate of HCC is almost equal to the incidence 
rate, this reflects the lack of effective treatment at diagnosis, 
especially in advanced HCC [2].  
Patients at a high risk of HCC should therefore undergo 
rigorous screening in order to detect HCC in its early form, at a 
stage where curative intervention is possible. 
Diagnosis of HCC is most often possible through cross-
sectional imaging alone, with histological analysis being the 
exception and not the rule.   
In high risk patients, nodules larger than 1 cm showing arterial 
enhancement and venous washout on post-contrast 
multidetector-row computed tomography (MDCT) or magnetic 
resonance imaging (MRI) are diagnosed as HCC, as per the 
American Association for the Study of Liver Diseases (AASLD) 
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and European Association for the Study of the Liver-European 
Organisation for Research and Treatment of Cancer (EASL-
EORTC) practice guidelines [3; 4].   
This pattern is highly specific (close to 100%), but not as 
sensitive [5].   
Our aim was to retrospectively review MRI studies performed 
with hepatobiliary contrast media in patients harbouring 
histologically proven HCCs on their liver explant post 
transplantation, and to identify the best combination of MRI 
imaging features useful in HCC diagnosis. 
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MATERIAL AND METHODS 
Study population. 
A total of 595 patients underwent liver transplantation 
between August 2004 and September 2012 in our hospital 
(ISMETT, Mediterranean Institute for Transplantation and 
Advanced Specialized Therapies, Palermo, Italy).   
An interdependent query against our electronic health records 
and RIS database showed that 162 subjects also had MRI 
within the 90 days preceding surgery.  A total of 65 patients 
were excluded.  Of these, 34 underwent liver transplantation 
for indications other than cirrhosis with or without HCC, 22 
had an MR examination which did not include the hepatobiliary 
phase, 5 had liver MRI performed using other contrast media, 
3 had an inadequate scan due to excessive motion artefact, 
and one patient was transplanted outside the Milan criteria. 
The imaging evaluation was performed at a mean of 
41.7±25.4 days prior to liver transplantation.  46 patients had 
undergone adjuvant percutaneous therapy for HCC 
(transarterial chemoembolization n=43, radiofrequency 
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ablation n=2, combination of TACE and RFA n=1).  Our final 
study cohort consisted of 97 consecutive subjects (Table 1). 
Table 1: Patient characteristics. 
Parameter Value 
Mean age (years) 58.5 (range: 41-70) 
Sex ratio (M:F) 78:19 
Aetiology of cirrhosis (n)  
Hepatitis C 57 
Hepatitis B 22 
Cryptogenic 5 
Alcohol 3 
Hepatitis B and C 2 
Other 8 
α-feto-protein level (ng/mL)  
≤ 10 45 
11-100 32 
101-399 15 
≥ 400 5 
MELD score (n)  
≤ 9 28 
10-14 46 
15-19 13 
20-24 4 
≥ 25 6 
MELDNa score (n)  
≤ 9 21 
10-14 35 
15-19 25 
20-24 8 
≥ 25 8 
 
Note: n = number of patients, MELD is the Model for End-Stage Liver 
Disease, MELD-Na = integrated MELD model including serum sodium. 
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MR protocol. 
Our MR examinations were performed using a super-
conducting magnet operating at 1.5 Tesla (Signa 1.5T HDxt, 
GE Healthcare, Milwaukee, WI, USA), with an 8-channel 
phased-array body coil centered on the liver.   
MR imaging was performed before and after Gd-BOPTA 
(MultiHance, Bracco SpA, Milan, Italy) injection (0.1 mmol/kg; 
2.4 mL/s) through an 18-21 gauge peripheral intravenous 
cannula using an automated dual-chamber injector (Spectris 
MR Injector; Medrad , PA, USA), followed by a 10 to 15 mL 
saline flush.   
The full hepatobiliary protocol is detailed in Table 2. 
 
 
 
 
 
 
 
 8 
Table 2: Technical parameters of the different sequences in our 
institutional MRI Liver protocol. 
Sequence Scan 
Matrix 
Slice 
Thickness 
(mm) 
Intersection 
gap (mm) 
Repetition 
time 
(msec) / 
Echo 
Time 
(msec) 
Flip 
Angle  
Echo 
Train 
Length 
Fat 
suppression 
FOV 
(cm) 
Reconstruction 
matrix (ZIP) 
Breath-
hold 
bSSFP 
(FIESTA) 
352x224 5 0.5 4.2 / 2.1 110 90 Spectral 
saturation 
40x40 512 
Breath-
hold T2-
weighted 
SSFSE  
384x224 5 0.5 756 / 102 90 14 No 40x40 512 
Breath-
hold T2-
weighted 
SSFSE fat 
sat 
288x224 5 0.5 701 / 120 90 14 Spectral 
saturation , 
Asset 
acceleration 
factor 2, 
average 1 
40x40 512 
T2-
weighted 
SPAIR 
416x256 5 0.5 10000 / 
120 
90 13 Asset factor 
1.75 , with 
spectral 
adiabatic 
inversion 
recovery 
40x40 512 
3D T1-
weighted 
in-phase 
and out-
of-phase 
320x192 4 Interleave 150 / 2.2-
4.2 
80 n/a ARC factor 1 40x40 512 
DWI  
b=400/800 
128x128 5 0.5 8000 / 2.2 90 n/a Asset factor 
2 with 
spectral 
saturation 
40x40 512 
T1-
weighted 
FSPGR 
LAVA 
384x224 4 Voxel 
continum 
1.8 /4.2 12 n/a ARC factor 
1,75 with 
selective 
spectral 
saturation 
40x32 409.6 
 
 
Note: 
FIESTA = Fast Imaging Employing Steady State Acquisition 
SSFSE = Single Shot Fast Spin Echo 
SPAIR = SPectral Attenuated Inversion Recovery 
DWI = Diffusion Weighted Imaging 
FSPGR = fast spoiled gradient echo 
LAVA = Liver Acquisition with Volume Acquisition 
ZIP = Zero Fill Interpolation Processing 
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Histopathological assessment. 
Histopathological examination of the explanted livers was 
considered the gold standard.  
Explanted livers were fixed in formalin and serially sliced in the 
transverse plane at 5 mm intervals corresponding as closely as 
possible to the imaging planes, as per institutional protocol. 
Nodule size, nodule location (as per Couinaud  classification), 
capsule, micro and macro-vascular, perineural invasion and 
nodal involvement were recorded.  
All lesions were sampled, fixed in formalin, embedded in 
paraffin, and cut into 3-4-micron-thick sections.  
The histopathology of all nodules was reviewed by a 
pathologist with 13 years’ experience in liver histopathology, 
blinded to the imaging findings. Nodules were classified into 
regenerative nodules, low-grade dysplastic nodules (LGDN), 
high grade dysplastic nodules, and grade I-III hepatocellular 
carcinoma nodules as per Edmondson and Steiner criteria [6; 
7].  
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Image analysis. 
A nodule-by-nodule analysis was jointly performed by two 
board-certified radiologists (with 5 and 11 years of experience 
in abdominal imaging, respectively) blinded to the reported 
radiological findings.   
Both radiologists had full access to the histopathology report.  
In cases where more than one Gd-BOPTA enhanced MRI was 
performed per patient during the three months preceding liver 
transplantation, only the latest examination was taken into 
consideration.   
Images were interpreted on a work station with a LCD 21’’ 
display with spatial resolution of 2 x 5 megapixels (Barco, 
Kortrijk, Belgium) running Centricity Picture Archiving & 
Communications System (PACS) version 3.2 (GE Healthcare).  
The signal intensity (hypo-, iso-, and hyper-intense) of the 
HCC nodules under study was analysed on all sequences 
performed as part of our institutional protocol.   
Arterial enhancement following injection of contrast was 
graded as either mild to moderate, or intense.   
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A ‘pseudocapsule’ was defined as a peri-nodular rim which 
enhances in the venous phases, or appears hypointense in the 
hepatobiliary phase [8; 9].   
 
Statistical analysis. 
Statistical analysis was performed by a biostatistician.   
A multiple logistic regression analysis was performed following 
pathological/radiological correlation, and the Odds Ratio (OR) 
was calculated for every parameter analyzed and adjusted for 
nodule size.   
Confidence Intervals (CI) were reported at 95%, and a p value 
of less than 0.05 was considered to be statistically significant 
in all statistical tests. 
Statistical analysis were performed using Stata 13.0 
(StataCorp, College Station, TX, USA) and R version 3.0.0 (R 
Development Core Team, Vienna, Austria) [10]. 
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RESULTS 
 
Histopathological findings. 
A total of 240 HCC nodules were reported in the 97 patients 
included in this study.   
47 HCCs had massive necrosis (intra-tumoral necrosis of ≥ 
90%) due to previous percutaneous locoregional therapy.  
These HCCs were eliminated from subsequent analysis.   
This resulted in a total of 193 HCCs, in 77 patients.   
Seventeen patients had 1 HCC nodule; twenty-two patients 
had 2 nodules; twelve patients had 3 nodules; and twenty-six 
patients had more than 3 nodules.  
Fig.1 shows some pathological examination with HCC. 
The mean HCC diameter was 17.8±10.2 mm.   
Tumour size was ≤10 mm in 28 HCC, 10–20 mm in 107 HCC 
and ≥20 mm in 58 HCC.   
Microvascular invasion was detected in 60.6 % (117/193) 
nodules.   
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Forty-eight patients had nodules other than HCC (68 
regenerative nodules, 8 low-grade dysplastic nodules, 19 high-
grade dysplastic nodules, 2 cholangiocarcinomas, 1 necrotic 
nodule). 
 
 
 
Fig.1: pathological examination resulting in liver cirrhosis and HCC. 
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MRI findings. 
Of the 193 HCCs seen on histopathology, 24.9% (48/193) 
were not detectable on imaging.  
The signal intensity of the remaining 145 HCCs were analysed 
on all sequences performed as part of our institutional 
protocol.   
The Odds Ratio (OR) was calculated for every parameter 
analysed and adjusted for nodule size, this is displayed in 
Tables 3 and 4, and also in Figure 2.   
MRI features that favour a diagnosis of HCC are shown in 
blue, while the findings that suggest a diagnosis of non-HCC 
are shown in red, with the respective ORs.   
Visualisation of a pseudocapsule on the venous or 
hepatobiliary phases (Fig.3) produced the highest OR (35.3, 
p<0.000).   
As expected, intense (OR 10.9, p<0.000) or moderate (OR 
2.2, p=0.003) arterial enhancement and hypointensity on the 
portal venous (OR 14.3, p<0.000) or equilibrium (OR 15.9, 
p<0.000) phases were found to predict HCC (Fig.4).   
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In addition, nodules showing hypointensity on the 
hepatobiliary phase (Fig.5) and mild-moderate T2 
hyperintensity (Fig.6) were also highly likely to represent HCC.  
In the former, an OR of 10.2 was observed (p<0.000).  
The OR was 14.3 in non-FS T2 weighted sequences, and 10.2 
in FS T2 weighted sequences (p<0.000). 
 
Table 3: MRI features that favour HCC. 
 
 
 
OR = Odds Ratio 
↔    Isointense 
↓     Hypointense 
↑     Hyperintense 
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Table 4: MRI features that favour non-HCC. 
 
 
 
↔    Isointense 
↓     Hypointense 
↑     Hyperintense 
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Fig.2: MR variables predicting HCC. 
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Fig.3: HCC with wash-in and wash-out; notice the pseudocapsule on 
equilibrium phase and on pathological examination. 
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Fig.4: HCC with typical pattern (wash-in and wash-out). Notice the 
hypointensity on hepatobiliary phase. 
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Fig.5: HCC with wash-in but without wash-out; however, the lesion showed 
hypointensity on hepatobiliary phase. 
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Fig.6: HCC with wash-in but without wash-out on equilibrium and hepatobiliary 
phases; however, the lesion showed hyperintensity on T2w sequence. 
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CONCLUSION  
 
MRI, unlike MDCT, is not simply a multi-phase post-contrast 
study.   
An array of T1 and T2 weighted sequences are performed, 
with the aim of portraying the inherent biological 
characteristics of the tissue under study, the vascular 
enhancement dynamics, and presence or absence of 
hepatocyte function when hepatobiliary contrast media are 
used.   
Our study confirms the usefulness of arterial enhancement 
and venous washout, as per the AALSD and EASL-EORTC 
guidelines, and also justifies incorporating hepatobiliary phase 
hypointensity in the diagnosis of HCC [11; 12].   
We have also shown that in patients with a high risk of HCC, 
nodules showing a pseudocapsule, mild-moderate T2 
hyperintensity, and T1 iso to hypointensity, are likely to 
represent HCC.   
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On the other hand, imaging features which point towards non-
HCC include T2 hypointensity, T1 hyperintensity, no arterial 
enhancement, and hyperintensity on the hepatobiliary phase. 
The current AASLD and EASL-EORTC practice guidelines rely 
exclusively on the contrast enhancement characteristics of 
HCC. In both guidelines, nodules over 1 cm in diameter 
showing wash-in of contrast during the arterial phase, 
followed by washout of contrast during the portal or delayed 
venous phase on either MDCT or MRI, should be regarded as 
HCC in patients with cirrhosis from any aetiology, or in non-
cirrhotic patients with chronic hepatitis B infection.   
There is no mention of hepatobiliary MRI contrast media in the 
AASLD and/or EASL-EORTC guidelines, in the latest updates 
published in 2011 and 2012, respectively. 
The Liver Imaging Reporting and Data System (LI-RADS) 
utilises ‘ancillary features’ that favour malignancy or benignity, 
and incorporates use of hepatobiliary contrast agents [13].   
LI-RADS ancillary features that favour malignancy include 
mild-moderate hepatobiliary phase hypointensity, T2 
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hyperintensity, restricted diffusion, intralesional fat and 
lesional haemorrhage.   
The presence of a pseudocapsule is a major feature in 
diagnosing HCC, together with venous washout and interval 
growth.  To date, LI-RADS has not been incorporated in the 
AALSD guidelines. 
In Japan HCC surveillance is performed by MRI performed 
with the use of hepatobiliary contrast media (Gd-EOB).   
MDCT is only performed whenever MRI is not available as per 
the Japan Society of Hepatology (JSH) practice guidelines 
[14].    
There is no dimensional cut-off above which HCC can be 
diagnosed.   
Nodules showing arterial enhancement, no venous washout, 
and hypointensity on the hepatobiliary phase are also 
diagnosed as HCC in the JSH guidelines.   
This rigorous approach is resulting in identification of 
potentially curable early-stage HCC – which amount to around 
62% of the patients diagnosed with HCC in Japan (only 
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around 30% of patients diagnosed with HCC are eligible for 
curable treatment in the West) [15].   
Apart from the intrinsic limitations of any retrospective study, 
our study had the following limitations.  
The most evident limitation is the potential miscorrelation 
between the histology section planes of liver explants and the 
MRI imaging section.  
We tried to reduce the risk of miscorrelation by measuring the 
distance between the lesion and liver capsule, and coupling 
this with segmental anatomy when correlating histological and 
radiological data.   
A significant limitation of our study is that DWI was only 
included in the standard protocol during the actual study 
period, and a significant number of the MRIs included in our 
study either lacked DWI, or had diffusion imaging performed 
with different b values (400, 600, or 800).   
A reliable statistical analysis could not be performed for these 
reasons.   
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Hwang J et al recently reported the potential of utilising 
diffusion weighted imaging (DWI) to distinguish hypovascular 
HCC from dysplastic nodules [16].   
This was noted by the study group of Renzulli M et al, that 
proposed the inclusion of DWI in the surveillance algorithm 
already being followed in Japan [17].   
Another limitation is that of having an artificial increase in 
sensitivity due to our selected patient population with a higher 
pre-test prevalence of HCC than that present in the general 
population.   
Finally, the pathological assessment done in this study was 
based on the International Working Party (1995) given that 
this study included data preceding the updated consensus 
published in 2009 by the International Consensus Group for 
Hepatocellular Neoplasia (ICGHN) [18]. 
In conclusion, MRI might provide auxiliary findings that 
facilitate diagnosis of HCC in nodules lacking the typical 
enhancement pattern.   
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The full potential of MRI should be exploited in patients with 
chronic liver disease, and any update to the existing European 
HCC surveillance guidelines should provide detailed 
information on a cross-platform MRI protocol aimed at 
detecting early HCC, with inclusion of hepatobiliary contrast 
media. 
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